Canadá - inglês - Health Canada

merck canada inc - eptifibatide - solution - 0.75mg - eptifibatide 0.75mg - platelet aggregation inhibitors

Canadá - inglês - Health Canada

merck canada inc - eptifibatide - solution - 2mg - eptifibatide 2mg - platelet aggregation inhibitors

Cingapura - inglês - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - eptifibatide - injection - 2 mg/ml - eptifibatide 2 mg/ml

Cingapura - inglês - HSA (Health Sciences Authority)

msd pharma (singapore) pte. ltd. - eptifibatide - injection - 0.75 mg/ml - eptifibatide 0.75 mg/ml

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - eptifibatide 0.75 mg/ml - solution for injection - 0.75 mg/ml - active: eptifibatide 0.75 mg/ml excipient: citric acid monohydrate water for injection - integrilin is indicated for the reduction of death and myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction (chest pain with stsegment depression >0.5 mm or definitive t-wave inversion >1 mm or transient st-segment elevation >0.5 mm of less than 30 minutes or persistent st-segment elevation >0.5 mm not requiring reperfusion therapy or thrombolytic agents, or chest pain in patients without persistent st-segment elevation with ck-mb greater than the upper limit of normal). integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. patients with unstable angina (ua) or non-q-wave myocardial infarction (nqmi) who are most likely to benefit from integrilin treatment are those at high risk of developing myocardial infarction within the first three to four days after onset of acute angina symptoms, including for instance those that are likely to undergo an early pci. integrilin is intended for use with aspirin, heparin and clopidigrel.

Nova Zelândia - inglês - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - eptifibatide 2 mg/ml - solution for injection - 2 mg/ml - active: eptifibatide 2 mg/ml excipient: citric acid monohydrate water for injection - integrilin is indicated for the reduction of death and myocardial infarction in patients presenting with unstable angina or non-q-wave myocardial infarction (chest pain with stsegment depression >0.5 mm or definitive t-wave inversion >1 mm or transient st-segment elevation >0.5 mm of less than 30 minutes or persistent st-segment elevation >0.5 mm not requiring reperfusion therapy or thrombolytic agents, or chest pain in patients without persistent st-segment elevation with ck-mb greater than the upper limit of normal). integrilin is indicated in patients who are managed with standard medical therapies and/or with percutaneous coronary intervention. patients with unstable angina (ua) or non-q-wave myocardial infarction (nqmi) who are most likely to benefit from integrilin treatment are those at high risk of developing myocardial infarction within the first three to four days after onset of acute angina symptoms, including for instance those that are likely to undergo an early pci. integrilin is intended for use with aspirin, heparin and clopidigrel.

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - eptifibatide - solution for injection - 2mg/1ml

Reino Unido - inglês - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - eptifibatide - solution for infusion - 750microgram/1ml

Armênia - inglês - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo operations uk ltd. - eptifibatide - solution for infusion - 0,75mg/ml

Armênia - inglês - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo operations uk ltd. - eptifibatide - solution for injection - 2mg/ml